ESC 365 - 6 to 12-month vs. 1-month dual antiplatelet therapy: comparative outcomes after aspirin cessation with HT supreme stent in the pooled PIONEER III and PIONEER IV trial analysis

Delegates Premium Access

6 to 12-month vs. 1-month dual antiplatelet therapy: comparative outcomes after aspirin cessation with HT supreme stent in the pooled PIONEER III and PIONEER IV trial analysis

Session: Tailoring antithrombotic therapy after PCI: balancing ischaemic and bleeding risks

Topic: Pharmacotherapy

Speaker: Professor Y. Onuma (Galway, IE)

Event: EAPCI Summit 2026

Congress Presentation

Add to my library

About the speaker

Professor Yoshinobu Onuma

Galway University Hospital, Galway (Ireland)

2 presentations

0 follower

6 more presentations in this session

Early oral anticoagulation monotherapy after PCI: insights from the POEM trial

Speaker: Doctor C. Pivato (Milan, IT)

Utilisation and outcomes of dual antiplatelet therapy in patients with active cancer presenting with acute myocardial infarction: insights from the TriNetX global registry

Speaker: Doctor A. Cole (Stoke on Trent, GB)

Do the ARC-HBR criteria predict major bleeding and ischaemic events in an all-comer AMI population? Insights from the MINAP and SWEDEHEART registries

Speaker: Doctor N. Weight (Stoke-on-Trent, GB)

One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in diabetic patients at high-bleeding risk: insights from the POEM trial

Speaker: Doctor L. Gramss (Milan, IT)

Ticagrelor 60 mg vs. 90 mg in elderly ACS patients with vs. without diabetes undergoing percutaneous coronary intervention

Speaker: Doctor A. Laino (Naples, IT)

Access the full session

Tailoring antithrombotic therapy after PCI: balancing ischaemic and bleeding risks

Speakers: Professor Y. Onuma, Doctor C. Pivato, Doctor A. Cole, Doctor N. Weight, Doctor L. Gramss...

About the event

EAPCI Summit 2026

19 February - 20 February 2026

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources